Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
Status:
Not yet recruiting
Trial end date:
2024-04-24
Target enrollment:
Participant gender:
Summary
This study will enroll male and female subjects who are 18 years of age or older with Primary
Myelofibrosis, post-polycythemia Vera Myelofibrosis, or post-essential Thrombocythemia
Myelofibrosis with severe thrombocytopenia (platelet count <50,000/µL) including subjects
with intermediate-1, intermediate-2, or high-risk MF according to the Dynamic International
Prognostic Scoring System (DIPSS).